Outlook Therapeutics Seeks FDA Meeting Regarding ONS-5010
ISELIN, N.J. — Outlook Therapeutics, Inc. (NASDAQ: OTLK), a biopharmaceutical company dedicated to improving treatment options for retinal diseases, has announced a significant step in its development process. The company has formally requested a Type A meeting with the U.S. Food and Drug Administration (FDA) to address the complete response letter (CRL) received for its biologics license application (BLA) resubmission for ONS-5010. This investigational ophthalmic formulation of bevacizumab is aimed at treating wet age-related macular degeneration (wet AMD).
The FDA's recent CRL acknowledged that the NORSE TWO pivotal trial successfully met its safety and efficacy endpoints. However, it also requested that Outlook Therapeutics submit confirmatory evidence of efficacy to support the application for ONS-5010. This Type A meeting is intended to help the company understand the specific details regarding the confirmatory evidence needed by the FDA to advance their application.
CEO Insights on the Type A Meeting
Bob Jahr, Chief Executive Officer of Outlook Therapeutics, expressed confidence that the upcoming meeting will provide the necessary clarity on the FDA's expectations. He stated, "We believe this Type A meeting will provide us with additional clarity on the FDA’s requirements to remedy the deficiency identified in the CRL." Jahr emphasized the company’s commitment to ensuring patient safety and the efficacy of its treatments. He noted the importance of a reliable alternative to compounded bevacizumab, which has faced concerns regarding its potency, sterility, and regulatory oversight.
Understanding ONS-5010/LYTENAVA™
ONS-5010, also known as LYTENAVA™, is a promising ophthalmic formulation of bevacizumab specifically developed for the treatment of wet AMD. It has received a centralized Marketing Authorization from the European Commission in the European Union and clearance from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for the same purpose. However, in the United States, ONS-5010 remains investigational until it receives FDA approval.
This formulation works by targeting vascular endothelial growth factor (VEGF) to inhibit its action and prevent further damage associated with wet AMD. Bevacizumab-vikg is known for its ability to bind with high affinity to all isoforms of VEGF, thereby thwarting its biological activity, which is crucial for reducing endothelial cell proliferation and vascular leakage within the retina.
Commercial Aspirations of Outlook Therapeutics
Outlook Therapeutics is set on the path to transforming the landscape of retinal disease treatment with ONS-5010/LYTENAVA™. As the first ophthalmic formulation of bevacizumab granted Marketing Authorization in the EU, Outlook has already commenced its commercial launch of LYTENAVA™ in Germany and the UK for treating wet AMD. In the U.S., if approved, ONS-5010 could represent a groundbreaking development as the first approved ophthalmic formulation of this treatment, potentially improving outcomes for patients battling retinal disorders.
In summary, Outlook Therapeutics, Inc. is pushing forward with its innovative approach to treating wet AMD through ONS-5010. The upcoming FDA meeting is a critical milestone in the company’s journey to bring this needed treatment to market, reaffirming its commitment to patient care and safety.
Frequently Asked Questions
What is the purpose of the Type A meeting with the FDA?
The Type A meeting aims to clarify the specific confirmatory evidence required by the FDA to support the application for ONS-5010.
What is ONS-5010?
ONS-5010, or LYTENAVA™, is an investigational ophthalmic formulation of bevacizumab developed for the treatment of wet AMD.
What has the FDA's response been to the NORSE TWO trial?
The FDA acknowledged that the NORSE TWO trial met its safety and efficacy endpoints but requested additional confirmatory evidence of efficacy.
Who is the CEO of Outlook Therapeutics?
Bob Jahr serves as the Chief Executive Officer of Outlook Therapeutics.
What impact could ONS-5010 have if approved in the U.S.?
If approved, ONS-5010 would be the first FDA-approved ophthalmic formulation of bevacizumab, enhancing treatment options for those with retinal diseases.
